Proksifan

S Vikipedije, slobodne enciklopedije
Proksifan
Nazivi
IUPAC naziv
4-[3-(benzyloxy)propyl]-1H-imidazole
Drugi nazivi
5-[3-(benzyloxy)propyl]-1H-imidazole
Identifikacija
3D model (Jmol)
ChemSpider
  • C1=CC=C(C=C1)COCCCC2=CN=CN2
Svojstva
C13H16N2O
Molarna masa 216,279 g/mol
Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
Reference infokutije

Proksifan je ligand histaminskog H3 receptora, koji je „proteanski agonist“. On proizvodi različite efekte u opsegu od punog agonista do antagonista, do inverznog agonista u različitim tkivima, u zavisnosti od nivoa konstitutivne aktivnosti histaminskog H3 receptora. To mu daje kompleksan profil aktivnosti in vivo.[3][4][5][6][7][8][9]

Reference[uredi | uredi izvor]

  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  уреди
  2. ^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1. 
  3. ^ Morisset, S.; Rouleau, A.; Ligneau, X.; Gbahou, F.; Tardivel-Lacombe, J.; Stark, H.; Schunack, W.; Ganellin, C. R.; Schwartz, J. C.; Arrang, J. M. (2000). „High constitutive activity of native H3 receptors regulates histamine neurons in brain”. Nature. 408 (6814): 860—864. PMID 11130725. S2CID 4391762. doi:10.1038/35048583. 
  4. ^ Fox, G. B.; Pan, J. B.; Esbenshade, T. A.; Bitner, R. S.; Nikkel, A. L.; Miller, T.; Kang, C. H.; Bennani, Y. L.; Black, L. A.; Faghih, R.; Hancock, A. A.; Decker, M. W. (2002). „Differential in vivo effects of H3 receptor ligands in a new mouse dipsogenia model”. Pharmacology, Biochemistry, and Behavior. 72 (3): 741—750. PMID 12175472. S2CID 45861589. doi:10.1016/s0091-3057(02)00745-1. 
  5. ^ Gbahou, F.; Rouleau, A.; Morisset, S.; Parmentier, R.; Crochet, S.; Lin, J. S.; Ligneau, X.; Tardivel-Lacombe, J.; Stark, H.; Schunack, W.; Ganellin, C. R.; Schwartz, J. C.; Arrang, J. M. (2003). „Protean agonism at histamine H3 receptors in vitro and in vivo”. Proceedings of the National Academy of Sciences of the United States of America. 100 (19): 11086—11091. PMC 196931Слободан приступ. PMID 12960366. doi:10.1073/pnas.1932276100Слободан приступ. 
  6. ^ Baldi, E.; Bucherelli, C.; Schunack, W.; Cenni, G.; Blandina, P.; Passani, M. B. (2005). „The H3 receptor protean agonist proxyfan enhances the expression of fear memory in the rat”. Neuropharmacology. 48 (2): 246—251. PMID 15695163. S2CID 24218659. doi:10.1016/j.neuropharm.2004.09.009. hdl:2158/220558. 
  7. ^ Krueger, Kathleen M.; Witte, David G.; Ireland-Denny, Lynne; Miller, Thomas R.; Baranowski, John L.; Buckner, Steve; Milicic, Ivan; Esbenshade, Timothy A.; Hancock, Arthur A. (2005). „G Protein-Dependent Pharmacology of Histamine H3 Receptor Ligands: Evidence for Heterogeneous Active State Receptor Conformations”. Journal of Pharmacology and Experimental Therapeutics. 314 (1): 271—281. PMID 15821027. S2CID 20470970. doi:10.1124/jpet.104.078865. 
  8. ^ Arrang, J. M.; Morisset, S.; Gbahou, F. (2007). „Constitutive activity of the histamine H3 receptor”. Trends in Pharmacological Sciences. 28 (7): 350—357. PMID 17573125. doi:10.1016/j.tips.2007.05.002. 
  9. ^ Baker, Jillian G. (2008). „Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells”. BMC Pharmacology. 8: 9. PMC 2430196Слободан приступ. PMID 18538007. doi:10.1186/1471-2210-8-9Слободан приступ. 

Spoljašnje veze[uredi | uredi izvor]